EUVIMEDEUVIMED entdecken
Open Access

Ceftriaxone for Methicillin-Susceptible Staphylococcus aureus Bacteremia: A Descriptive Case Series of Nine Patients During a Cefazolin Shortage

Tomohide Okinaka, Hidenobu Koga, Takashi Matono

Cureus · 06.10.2025

DOI: 10.7759/cureus.93977 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Cureus, erschienen am 06.10.2025. Verfasst von Tomohide Okinaka und 2 weiteren Autor:innen. Beteiligte Einrichtung: Department of Infectious Diseases, Aso Iizuka Hospital, Fukuoka, JPN. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 12 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Introduction

Cefazolin is the standard treatment for methicillin-susceptible Staphylococcus aureus (MSSA) bacteremia. During drug shortages, alternative agents such as ceftriaxone may be considered, though evidence supporting its efficacy is conflicting. We aim to describe the clinical characteristics and outcomes of patients with MSSA bacteremia treated with ceftriaxone during a nationwide cefazolin shortage in Japan.

Methods

We conducted a retrospective case series at a single tertiary care hospital. We reviewed the records of nine adult patients hospitalized between April 2019 and March 2020 who received ceftriaxone for at least half of their intravenous therapy duration for MSSA bacteremia.

Results

The median age of the nine patients was 69 years. The infection was nosocomial in seven (78%) patients. The most common sources of infection were catheter-related. All patients achieved clinical resolution. The median duration of total intravenous antibiotic therapy was 31 days. No deaths occurred within 30 days, and no microbiological relapses were observed during a 90-day follow-up period.

Conclusion

In this small case series, ceftriaxone was associated with favorable outcomes in nine patients with MSSA bacteremia, the majority of whom had non-endocarditis, catheter-related infections. While these observations are encouraging, cefazolin remains the preferred agent. The role of ceftriaxone should be further evaluated in larger studies.

Schlagwörter

Stichwörter der Autor:innen

case-seriescatheter-related bloodstream infection (crbsi)cefazoliniv ceftriaxonemethicillin-susceptible staphylococcus aureus bacteremia

Autor:innen und Institutionen

  • Department of Infectious Diseases, Aso Iizuka Hospital, Fukuoka, JPN.
  • Department of Clinical Research Support Office, Aso Iizuka Hospital, Fukuoka, JPN.
  • Division of Infectious Disease and Hospital Epidemiology, Saga University Hospital, Saga, JPN.

Zitieren

APA

Okinaka, T., Koga, H., & Matono, T. (2025). Ceftriaxone for Methicillin-Susceptible Staphylococcus aureus Bacteremia: A Descriptive Case Series of Nine Patients During a Cefazolin Shortage. Cureus. https://doi.org/10.7759/cureus.93977

Vancouver

Okinaka T, Koga H, Matono T. Ceftriaxone for Methicillin-Susceptible Staphylococcus aureus Bacteremia: A Descriptive Case Series of Nine Patients During a Cefazolin Shortage. Cureus. 2025. doi:10.7759/cureus.93977

BibTeX
@article{Okinaka2025,
  author = {Okinaka, Tomohide and Koga, Hidenobu and Matono, Takashi},
  title = {Ceftriaxone for Methicillin-Susceptible Staphylococcus aureus Bacteremia: A Descriptive Case Series of Nine Patients During a Cefazolin Shortage},
  journal = {Cureus},
  year = {2025},
  doi = {10.7759/cureus.93977}
}
Kostenlos starten →